Eli Lilly Just Cut Off 50 Hospital Systems. The Reason Will Surprise You.
Eli Lilly cut off 340B drug discounts to over 1,000 hospitals that refused to hand over detailed dispensing data, sparking a furious backlash from hospital groups demanding federal intervention. With billions in safety-net funding at stake and HRSA staying silent, this fight could reshape how America's most vulnerable hospitals stay afloat.
Imagine your internet provider suddenly demanding a detailed log of every website you visit before they'll honor your monthly rate. That's roughly what Eli Lilly just did to hospitals across the country.
As of mid-June 2026, Lilly has stopped giving 340B drug discounts to hospitals that refused to hand over detailed dispensing data. The company says it's fighting waste and abuse. Hospitals say it's an illegal power grab. And the federal agency that's supposed to referee? Silent.
The Program That Funds the Safety Net
A quick primer on why this matters. The 340B Drug Pricing Program requires drug companies to sell medications to qualifying hospitals at steep discounts, typically 25% to 50% off. In return, those hospitals serve low-income and uninsured patients. It's the government's way of saying: "You want access to Medicare and Medicaid revenue? Then help fund the safety net."
The program has grown massive. In 2024, total 340B purchases hit $81.4 billion, with safety-net hospitals accounting for the lion's share. Hospitals buy drugs cheap, get reimbursed at standard rates, and pocket the difference. That margin funds everything from rural emergency rooms to urban HIV clinics.
Drug companies have never loved this arrangement. They see billions in revenue evaporating through a program they believe has ballooned far beyond its original intent. And Lilly decided to do something about it.
The Paperwork Power Play
Starting in February 2026, Lilly rolled out a new policy: every hospital buying Lilly drugs at 340B prices must submit claims-level dispensing data through a platform called 340B ESP. Not just for contract pharmacies (outside pharmacies that fill prescriptions on a hospital's behalf), but for in-house pharmacies too. That was the new part, and it was unprecedented.
The requirements aren't trivial. Hospitals must provide 18 data fields for in-house pharmacy claims and 14 fields for medical claims. Every dispense of every Lilly drug has to be reported within (or 60 days for certain infused medications like the cancer drug Cyramza). Miss the window, and you lose your discounts.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
45 days
Lilly frames this as a program-integrity measure, a way to catch duplicate discounts and misuse. Hospitals see it differently. They call it a manufacturer inventing rules that don't exist in federal law, then punishing anyone who won't play along.
June's Showdown
On June 1, Lilly sent notices to about 1,000 non-compliant hospitals: submit your data within five business days, or lose your pricing. By mid-June, the company had followed through. Approximately 50 hospital systems that hadn't complied found themselves cut off from 340B discounts on Lilly's entire drug portfolio.
To put that in perspective, over 2,300 hospitals did comply. But the holdouts aren't small players, and they're furious.
The American Hospital Association called Lilly's actions "unlawful" and accused the company of trying to "hijack the 340B program through burdensome claims-data demands." America's Essential Hospitals, a group representing major safety-net systems, fired off a formal letter to HRSA Administrator Thomas Engels on June 18. Their demands were specific: force Lilly to restore discounts immediately, issue refunds for all overcharges, and hit the company with civil monetary penalties.
340B Health, another advocacy group, called it an "unprecedented attempt to rewrite the 340B rules without congressional approval."
Why HRSA's Silence Is Deafening
Here's the awkward part. The Health Resources and Services Administration (HRSA), the federal agency that oversees the 340B program, has declined to comment on whether it plans to intervene. It hasn't taken public enforcement action against Lilly's in-house data mandate.
The AHA has pointedly reminded HRSA that it moved quickly in 2024 when drugmakers tried separate rebate policies. The implication: you acted fast before; what's different now?
The answer, unfortunately, is the courts. Federal appellate courts have consistently sided with manufacturers in recent 340B disputes, holding that drug companies can impose conditions on how hospitals access 340B pricing, as long as they still make a "bona fide offer" at or below the ceiling price somewhere in the supply chain. A 2024 D.C. Circuit ruling further weakened HRSA's hand by ruling that courts don't have to defer to the agency's interpretation of 340B law.
So HRSA finds itself in a bind. It may believe Lilly is wrong, but it also knows that any enforcement action could get swatted down in court. That leaves hospitals in limbo: comply with Lilly's demands and spend "hundreds of thousands of dollars" (AHA's estimate) on data infrastructure, or refuse and lose access to discounted drugs that fund their most vulnerable programs.
The Bigger Picture: A $8 Billion Fight
Lilly isn't alone in restricting 340B. Since 2020, multiple manufacturers have been tightening the screws. By mid-2023, 23 manufacturers had imposed restrictions affecting roughly $8.4 billion in annual 340B savings tied to contract pharmacy relationships. Lilly's move to extend data requirements to in-house pharmacies is just the latest escalation, and potentially the most consequential.
Think of it like a slow-motion siege. First, drug companies restricted discounts at contract pharmacies. Now they're coming for the hospitals' own pharmacies. If other manufacturers follow Lilly's playbook (and history suggests they will), the entire financial model that safety-net hospitals rely on could erode.
Ten states are currently exempt from Lilly's policy, including Colorado, Oregon, Tennessee, and Vermont. But for hospitals everywhere else, the clock is ticking.
What Happens Next
The AHA is calling on Congress to "immediately use its oversight authority" and force HHS to take a position. Hospitals have also floated the idea of a neutral third-party clearinghouse that could share data without giving manufacturers direct access to hospital-level dispensing records.
But without HRSA stepping in or Congress acting, Lilly holds the leverage. The company controls the pricing, it built the data platform, and it set the deadlines. Hospitals that want their discounts have to play by Lilly's rules, whether those rules are legal or not.
This fight is about more than paperwork. It's about who controls a $66 billion drug program and what happens to the hospitals that depend on it. Right now, the answer seems to be: the company with the most expensive drugs in the room.
Deals & M&A4 min read
Eli Lilly Just Spent $6.3 Billion to Fix a Problem You Didn't Know It Had
Eli Lilly is paying up to $7.8 billion for Centessa Pharmaceuticals and its experimental sleep disorder drugs. It's the biggest signal yet that the GLP-1 king is building a second empire, and the orexin agonist race just got a lot more interesting.
